The Department of Health has asked the Institute to conduct an appraisal of nivolumab for previously treated advanced hepatocellular carcinoma. We have now been informed by the company that it will no longer be pursuing a licensing application, therefore, NICE has decided to suspend this appraisal from its current work programme. For more detailed information please refer to the EMA website. The discussion of this appraisal planned for Thursday 12 October 2017 has been cancelled. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.
 
Status Suspended
Process STA
ID number 1141

Project Team

Project lead Stephanie Yates

Email enquiries

Consultees

Companies sponsors Bristol-Myers Squibb (nivolumab)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups British Liver Trust
Professional groups Association of Cancer Physicians
  British Association of the Study of the Liver
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Associated public health groups None
Comparator companies None
Evidence review group Warwick Evidence
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services committee
Relevant research groups Foundation for Liver Research
  Institute of Cancer Research
  National Cancer Research Institute

Timeline

Key events during the development of the guidance:

Date Update
15 September 2017 Suspended: EMA website, The Department of Health has asked the Institute to conduct an appraisal of nivolumab for previously treated advanced hepatocellular carcinoma. We have now been informed by the company that it will no longer be pursuing a licensing application, therefore, NICE has decided to suspend this appraisal from its current work programme. For more detailed information please refer to the EMA website. The discussion of this appraisal planned for Thursday 12 October 2017 has been cancelled. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.
15 September 2017 The Department of Health has asked the Institute to conduct an appraisal of nivolumab for previously treated advanced hepatocellular carcinoma. We have now been informed by the company that it will no longer be pursuing a licensing application, therefore, NICE has decided to suspend this appraisal from its current work programme. For more detailed information please refer to the EMA website. The discussion of this appraisal planned for Thursday 12 October 2017 has been cancelled. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.
15 May 2017 Invitation to participate
07 March 2017 - 28 March 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
01 March 2017 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance